Dr. Mitchell Blutt works as a clinical assistant professor of medicine at Weill Cornell Medical College. A graduate of the University of Pennsylvania’s medical school, Dr. Mitchell Blutt served on the board of Penn Medicine, the university’s medical center, which trains doctors and advances medical research in addition to providing patient care.
At Penn Medicine, conducting research is an integral part of developing effective treatments. The process of turning research done in a laboratory into new drugs or treatment protocols that can be used to improve patients’ health is called translational research or “bench to bedside” medicine. The Institute for Translational Medicine and Therapeutics at Penn Medicine supports this work through providing the research facilities and faculty to turn medical research into treatments and procedures that can be applied in clinical settings to help patients heal.
In November 2016, research by University of Pennsylvania faculty member Mitchell Lazar, MD, PhD, illustrated a complementary relationship between two molecules in the liver – one that stores fat and one that helps burn fat. If the molecules are both removed in mice, toxic fats build up and can cause nonalcoholic steatohepatitis, also called non-alcoholic fatty liver disease. An important discovery, the findings may be used by those studying obesity to eventually develop treatments or drugs to reverse or prevent liver damage caused by overeating.